Takeda Pharmaceutical has entered into a collaboration and licensing agreement with US-based gene therapy company StrideBio for the development of in vivo AAV based treatments for neurological disorders.
Multi-target deal will utilize StrideBio’s platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich’s Ataxia